Clinical Evidence Supports Rapid SUBLOCADE® Induction as a Strategy to Improve Retention in Opioid Use Disorder Treatment

Indivior PLC (Nasdaq: INDV) this week published compelling results from a multicenter, open-label clinical trial published in JAMA Network Open. Two approaches were evaluated for initiating treatment ...
Morningstar

Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) Injection

Rapid Initiation Protocol Reduces Time to Treatment with SUBLOCADE® From One Week to One Hour, A Significant Advancement in the Treatment of Moderate to Severe Opioid Use Disorder (OUD) These FDA ...
Nasdaq

Indivior: FDA Approval Of SUBLOCADE Label Changes Delayed

(RTTNews) - Indivior PLC (INDV, INDV.L), a specialty pharmaceutical company, announced Wednesday that the U.S. Food and Drug Administration has informed that the final review of the SUBLOCADE ...
Hosted on MSN

HCSO announces new program to address opioid crisis

This week the Humboldt County Sheriff’s Office announced that it would be launching a new program to address opioid addiction in the community. Beginning this October, HCSO’s program “will provide ...